Earnings call transcript: Henry Schein tops Q3 2026 profit view, shares fall

Henry Schein reported Q3 2026 non-GAAP EPS of $1.56, beating the $1.36 consensus by $0.20, while revenue of $3.47 billion narrowly missed the $3.48 billion forecast; sales rose 4.0% year over year and non-GAAP operating margin expanded 20bps to 8.03%. The company raised 2026 non-GAAP EPS guidance to $5.50–$5.56 from $5.29–$5.39, citing improved underlying performance and tariff refunds, while keeping revenue growth guidance at 4.5%–5.5%. Shares fell 5.33% premarket to $82, as investors appeared to weigh the slight revenue miss and outlook against the earnings beat; the quarter included a $0.19-per-share tariff refund benefit.

Analysis

The earnings headline overstates the quality of the beat: the tariff refund added $0.19 per share and is unlikely to recur at the same level. The more durable signal is volume-led dental growth alongside modest margin expansion, but management’s market-share evidence is internal and should be tested against gross-margin mix and customer retention. Own-brand and exclusive-product gains could improve customer stickiness and economics; the counter-risk is that promotions and lower-priced substitutions win volume without equivalent profit conversion. That distinction matters more than the small revenue miss.

The selloff may reflect uncertainty over the earnings base entering 2027, not a clear deterioration in demand. The unchanged sales outlook, Q4 growth investments and CFO transition raise execution risk; management’s double-digit 2027 EPS ambition is not yet formal guidance. Over the next 1–3 months, watch Q4 dental order trends, gross margin, and whether investment spending converts into active customers and share of wallet. Over 6–18 months, cloud practice software could reinforce distribution retention, but that cross-sell benefit remains a company thesis, not yet quantified evidence. Patterson Companies and other dental distributors could face share pressure if HSIC’s gains persist; suppliers may also face greater private-label substitution. Falsifiers: a cut to sales guidance, dental volume deceleration, margin giveback, or value-creation savings failing to appear in operating results.

Key Decisions for Investors

• Consider a staged HSIC long only after regular-session price action stabilizes following the premarket decline; do not treat the company’s buybacks as a price floor. Reassess if the post-earnings low breaks or management cuts the sales outlook.
• For the next earnings cycle, track dental gross-margin mix and customer activity alongside sales: sustained volume gains with stable margins support the share-gain thesis; promotion-led growth with margin erosion weakens it.
• Treat 2027 double-digit EPS growth as an unconfirmed catalyst, not a base-case estimate. Require formal guidance that separates recurring operating improvement from the tariff benefit before underwriting that growth.
• Keep Patterson Companies on a relative-performance watchlist rather than initiating a pair trade now; the article provides no comparable results or valuation evidence to size a short.